Sandoz launches semaglutide diabetes drug in Brazil, targets emerging market growth

Sandoz is entering the Brazilian market with a semaglutide-based diabetes medication, signaling a strategic push into emerging markets for biosimilars. The move capitalizes on Brazil's large diabetes population and growing demand for affordable GLP-1 therapies, but faces regulatory and competitive risks. This marks a notable expansion by a major generic player into a high-growth market.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works